Amylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals, Inc. (AMLX) priced its initial public offering on Jan 10, 2022 at $19.00 per share, raising $190M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $1.07B. Goldman Sachs was lead-left underwriter, joined by Leerink Partners, Evercore ISI and H.C. Wainwright. Goodwin Procter advised the company and WilmerHale advised the underwriters.

Amylyx Pharmaceuticals, Inc. develops therapies for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases by keeping neurons alive. Its product candidate AMX0035 is being pursued for commercialization, including a New Drug Submission in Canada.

Status

IPO

Ticker

AMLX

Exchange

Nasdaq Global Select

Priced

Jan 10, 2022

IPO price

$19.00

Raised

$190M

Market cap at IPO price

$1.07B

First filed

Dec 16, 2021

Underwriters

Goldman Sachs, Leerink Partners, Evercore ISI and H.C. Wainwright

Company counsel

Goodwin Procter

Underwriters' counsel

WilmerHale

Sector

Biotech & pharma

Country / state

MA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.